UNSPSC 51152028: Dotefonium

This classification denotes a muscle relaxant with the molecular formula C20H27N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F41A22A3KV, chemically known as pyrrolidinium, 1-methyl-1-(2-(n-methyl-alpha-2-thienylmandelamido)ethyl)- but generally known as dotefonium, which bears US NIH Compound Identifier 71913. European Medicines Agency schedules Dotefonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06379MIG.

The term DOTEFONIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25, No. 10 1971, List 11). As of Q4 2014, DOTEFONIUM remains the US FDA Preferred Term for this commodity. Dotefonium bears US NLM identifiers UMLS ID C2828324 and NCI Concept Code C87490. SMILES: CN(CC[N+]1(CCCC1)C)C(=O)C(C2=CC=CC=C2)(C3=CC=CS3)O.

UNSPSC 51152028 Dotefonium is a Commodity code that covers the procurement of naloxone and drug deactivation systems by state and local health agencies and counties. State and local governments use this code to acquire emergency medical supplies and harm-reduction products — specifically naloxone (an opioid antagonist used to reverse overdose) and safe drug deactivation or disposal systems — for community health initiatives, emergency response programs, and public health infrastructure. Issuing bodies under this code include county health departments and state health and human services agencies. Procurement typically follows competitive bidding processes with quarterly or regular delivery schedules to centralized health facilities.

Recent activity shows geographic concentration in the Southeast and South. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription and pharmaceutical fulfillment programs, including drug deactivation capabilities, with a response deadline of April 3, 2026. The Seminole County procurement includes a two-year initial term with a one-year renewal option, requires E-Verify compliance and drug-free workplace certification, and mandates workers' compensation, commercial general liability, and professional liability insurance. The Texas RFI is exploratory and designed to inform future formal procurement strategy around direct contracting models and value-based agreements rather than commit to immediate contract awards.